Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization

Cited by (167)

Items 101–167 of 167

1. Research advances in current drugs targeting hyperlipidemia (Review)
   Hanwei Zhao, Yao Wang, Yaqing Li, Ran Cheng, Wenge Chen · 2025 · Molecular Medicine Reports
2. Familial hypobetalipoproteinemia: Analysis of three Spanish cases with two new mutations in the APOB gene
   R. Martín-Morales, Juan de Dios García-Díaz, Patrizia Tarugi, Pedro González‐Santos, P. Saavedra-Vallejo, Lucia Magnolo, José María Mesa-Latorre, Enza Di Leo, Pedro Valdivielso · 2013 · Gene
3. Clinical and genetic analysis of a family diagnosed with familial hypobetalipoproteinemia in which the proband was diagnosed with diabetes mellitus
   Xiaoli Wang, Dongdong Wang, Zhongyan Shan · 2015 · Atherosclerosis
4. Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C
   Charlotte de Gier, Manuela Neyer, Sophie Draxler-Dworzak, Margot Baumgartner-Kaut, Thomas Müller-Sacherer, Klaus Arbeiter, Susanne Greber‐Platzer · 2025 · Atherosclerosis
5. Evolving ANGPTL-based lipid-lowering strategies and beyond
   Dominic S. Ng · 2021 · Current Opinion in Lipidology
6. Bypassing the LDL Receptor in Familial Hypercholesterolemia
   Sander Kersten · 2020 · New England Journal of Medicine
7. Genetics of remnant cholesterol
   Anders Berg Wulff, Børge Grønne Nordestgaard · 2025 · Current Opinion in Lipidology
8. What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?
   Janina M. Jeff, Gina Marie Peloso, Ron Do · 2016 · Current Opinion in Lipidology
9. ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content
   Alessandra Pinzon Grimaldos, Ilenia Pacella, Simone Bini, Gloria Tucci, Ilenia Cammarata, Alessia Di Costanzo, Ilenia Minicocci, Laura D’Erasmo, Marcello Arca, Silvia Piconese · 2022 · Atherosclerosis
10. Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice
    Yanli Ma, Di Xie, Junchao Liu, Xinli Han, Hong Xu, Yu Chen · 2023 · International Immunopharmacology
11. Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178
    Katsuyuki Nakajima, Junji Kobayashi · 2013 · Expert Opinion on Therapeutic Patents
12. Rare Diseases Related with Lipoprotein Metabolism
    Hongwen Zhou, Yingyun Gong, Qinyi Wu, Xuan Ye, Baowen Yu, Chenyan Lu, Wanzi Jiang, Jingya Ye, Zhenzhen Fu · 2020 · Advances in experimental medicine and biology
13. ANGPLT3: A novel modulator of lipid metabolism
    Mohamed Sayed Hassan · 2015 · Global Cardiology Science and Practice
14. Lipoprotein and Lipid Metabolism
    Robert Alexander Hegele · 2013 · Elsevier eBooks
15. ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting
    Shuwei Weng, Chen Ding, Jinxiu Lin, Dajun Chai · 2026 · Frontiers in Endocrinology
16. Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource
    Christopher Koch, Shareef Khalid, Maleeha Zaman Khan, Shruthi Bandyadka, Brian Doyon, Daniel P. Denning, Muhammad Jahanzaib, Muhammad Rehan Mian, Wafa Gul, Muhammad Bilal Liaqat et al. · 2026 · Nature
17. Familial combined hypolipidemia due to mutations in theANGPTL3gene
    Sebastiano Calandra, Patrizia Tarugi, Maurizio Rocco Averna, Stefano Bertolini · 2013 · Clinical Lipidology
18. Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?
    Andrea Volta, G. Kees Hovingh, Aldo Grefhorst · 2018 · Current Opinion in Lipidology
19. New therapeutic approaches for the treatment of hypertriglyceridemia
    Ioanna Gouni‐Berthold, Jonas Schwarz · 2022 · Herz
20. A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3
    Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li, Miao Yu, Fan Ping, Tong Wang, Xiaojing Wang · 2018 · BioMed Research International
21. ANGPTL3 Mutations in Unrelated Chinese Han Patients with Familial Hypercholesterolemia
    Yunyun Yang, Song Yang, Xiaolu Jiao, Juan Li, Miaomiao Zhu, Luya Wang, Yanwen Qin · 2019 · Current Pharmaceutical Design
22. Genetically determined deficiency of ANGPTL3 does not alter HDL ability to preserve endothelial homeostasis
    Alice Ossoli, Ilenia Minicocci, Marta Turri, Alessia Di Costanzo, Laura D’Erasmo, Simone Bini, Linda Montavoci, Fabrizio Veglia, Laura Calabresi, Marcello Arca · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
23. Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia
    Miriam Larouche, Poulabi Banerjee, Diane Brisson, Robert C. Pordy, Daniel Gaudet · 2025 · Journal of the Endocrine Society
24. Pharmacogenomic approaches to lipid-regulating trials
    Marie-Jeanne Bertrand, Marie‐Pierre Dubé, Jean‐Claude Tardif · 2016 · Current Opinion in Lipidology
25. Lipoprotein and Lipid Metabolism
    Robert Alexander Hegele · 2021 · Elsevier eBooks
26. New and Emerging Therapies for Dyslipidemia
    Alberto Zambon, Maurizio Rocco Averna, Laura D’Erasmo, Marcello Arca, Alberico Luigi Catapano · 2022 · Endocrinology and Metabolism Clinics of North America
27. ANGPTL3 Variants Associate with Lower Levels of Irisin and C-Peptide in a Cohort of Arab Individuals
    Muath Alanbaei, Mohamed Abu‐Farha, Prashantha Hebbar, Motasem Melhem, Betty Chandy, Emil Anoop, Preethi Cherian, Irina Al‐Khairi, Fadi Alkayal, Fahd Al‐Mulla et al. · 2021 · Genes
28. Effect of thyroid function on pre-β1 high-density lipoprotein levels in patients with Graves’ disease undergoing radioiodine treatment
    Zhenqin Cai, Lingxin Deng, Yunqin Chen, Yan Ling · 2022 · Endocrine
29. Hipotrigliceridemias/hipolipidemias
    Sergio Martínez‐Hervás, José Tomás Real-Collado, Juan Francisco Ascaso-Gimilio · 2021 · Clínica e Investigación en Arteriosclerosis
30. A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
    Masood Khaksar Toroghi, Jim Bosley, Lyn M. Powell, Yi Zhang, Feng Yang, Xia Pu, John D. Davis, Nidal H. Al-Huniti · 2021 · CPT Pharmacometrics & Systems Pharmacology
31. Rare coding variants in CHRNB2 reduce the likelihood of smoking
    Veera Manikandan Rajagopal, Kyoko Watanabe, Joelle S. Mbatchou, Ariane H. Ayer, Peter Quon, Deepika Sharma, Michael D. Kessler, Kavita Praveen, Sahar Gelfman, Neelroop Parikshak et al. · 2022 · medRxiv
32. Familial Hypercholesterolemia
    Angela Pirillo, Manuela Casula, Andrea Baragetti, Alberico Luigi Catapano · 2024 · Elsevier eBooks
33. In Silico Description of the Direct Inhibition Mechanism of Endothelial Lipase by ANGPTL3
    Linda Montavoci, Omar Ben Mariem, Simona Saporiti, Tommaso Laurenzi, Luca Palazzolo, Alice Ossoli, Uliano Guerrini, Laura Calabresi, Ivano Eberini · 2024 · International Journal of Molecular Sciences
34. Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans
    Marcello Arca, Elias Björnson, Laura D’Erasmo, Alessia Di Costanzo, Simone Bini, Ilenia Minicocci, Daniele Tramontano, Stella Covino, Giuseppe Ciarlo, Manuela Lombardi et al. · 2026 · Journal of Internal Medicine
35. Novel protein-truncating variant in the APOB gene may protect from coronary artery disease and adverse cardiovascular events
    Gabriele Mango, Nicola Osti, Silvia Udali, Anna Vareschi, Giovanni Malerba, Alejandro Giorgetti, Francesca Pizzolo, Simonetta Friso, Domenico Girelli, Oliviero Olivieri et al. · 2022 · Atherosclerosis Plus
36. Association of a genetic variant in angiopoietin‐like 3 with serum HDL‐C and risk of cardiovascular disease: A study of the MASHAD cohort over 6 years
    Malihe Aghasizadeh, Asieh Ahmadihoseini, Reza Sahebi, Toba Kazemi, Parisa Asadiyan‐Sohan, Habibollah Esmaily, Sara Samadi, Amir Avan, Gordon A. Ferns, Saeede Khosravi Bizhaem et al. · 2024 · Molecular Genetics & Genomic Medicine
37. Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia
    Sébastien Bihorel, Robert K. Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert C. Pordy, John D. Davis, Albert Thomas DiCioccio, Lutz O. Harnisch · 2025 · CPT Pharmacometrics & Systems Pharmacology
38. Perspective: Hepatocyte-Directed Base Editing as Novel Treatment for Human Dyslipidemia—Current Status and Remaining Challenges
    Menno Hoekstra, Miranda Van Eck, Theo J.C. van Berkel · 2023 · Arteriosclerosis Thrombosis and Vascular Biology
39. Genetic Disorders of HDL Metabolism
    Jessica Sparks Lilley, MacRae F. Linton, Sergio Fazio · 2015 · Contemporary Endocrinology
40. Endogenous and exogenous factors affecting lipoprotein lipase activity
    Mikael Larsson · 2014 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
41. Homozygote familiäre Hypercholesterinämie - Teil 2
    Klaus Georg Parhofer, Anja Vogt, Christoph J. Binder, Christoph F. Ebenbichler, Susanne Greber‐Platzer, Jürgen Harreiter, Ursula Kassner, Gerald Klose, I.M. Lang, Martin Merkel et al. · 2024 · CardioVasc
42. Health Outcomes Associated with Hypolipidemia: a Scoping Review
    Seungcheol Hong, Dong-jun Choi, Ji-cheon Jeong · 2025 · The Journal of Internal Korean Medicine
43. Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
    Shuai-Jie Huang, Ping Hsin Huang, Nan-Nan Song, Xian-hui Jia, Hong‐Li Gao, Zhiyuan Lu, Xiaolan Wen · 2025 · Experimental and Molecular Pathology
44. ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress
    Yuanzhen Zhang, Xiaozhi Hu, Zhonglian Cao, Kaicheng Zhou, Yun Sun, Yong Deng, Shuwen Xu, Yanyang Nan, Xi Gai, Mengyang Li et al. · 2025 · International Journal of Biological Macromolecules
45. Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice
    Ying Hou, Xin Zhang, Xia Sun, Qiaohong Qin, Min Jia, Xingli Su, Yulong Chen · 2026 · Arteriosclerosis Thrombosis and Vascular Biology
46. Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination
    Marta Biolo, Maria Giovanna Lupo, Giorgia Marodin, Camilla Portinari, Alberto Zambon, Sandra Bertocco, Lorenzo Previato, Paolo Simioni, Nicola Ferri, Sabina Zambon · 2026 · Journal of clinical lipidology
47. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia
    Barbara S. Wiggins · 2021 · Journal of Cardiovascular Pharmacology
48. Rare monogenic disorders of cholesterol metabolism
    Małgorzata Bednarska‐Makaruk, Agnieszka Ługowska · 2022 · Elsevier eBooks
49. Molecular Genetics of Hypobetalipoproteinaemia and Abetalipoproteinaemia
    Amanda J. Hooper, John R. Burnett · 2013 · Encyclopedia of Life Sciences
50. Recent Insights into the Genetics of Plasma Triglycerides and Possible Causal Mechanisms in Cardiovascular Disease
    Christopher T. Johansen, Austin MacDonald, Robert Alexander Hegele · 2013 · Wiley eBooks
51. Does liver-derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives
    Marianna Maranghi, Giusy Tiseo, Marcello Arca · 2013 · Clinical Lipidology
52. Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation
    Anna Tikka, Jarkko Soronen, Pirkka‐Pekka Laurila, Jari Metso, Christian Ehnholm, Matti Jauhiainen · 2015 · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
53. Efecto de la inhibición de la proteína símil angiopoyetina tipo 3 (ANGPTL3)
    Gerardo D. Elikir · 2021 · Revista del Hospital Italiano de Buenos Aires
54. Novel APOB mutation in familial hypobetalipoproteinemia
    Mónica Doménech, Isabel Llano‐Rivas, Vicente Arroyo, Emilio Ortega · 2021 · Journal of clinical lipidology
55. Familial hypobetalipoproteinemia and abetalipoproteinemia
    Francine K. Welty · 2022 · Elsevier eBooks
56. Primer hipolipoproteinemili hastalarda monosit/yüksek yoğunluklu lipoprotein kolesterol oranı
    Melisa Şahin Tekin · 2022 · DergiPark (Istanbul University)
57. Association of Genotypes of ANGPTL3 with Vitamin D and Calcium Concentration in Cardiovascular Disease
    Malihe Aghasizadeh, Mahmoud Ghanei, Sahar Ghoflchi, Parisa Asadiyan‐Sohan, Mohammad Haghani, Toba Kazemi, Habibollah Esmaily, Amir Avan, Gordon A. Ferns, Ebrahim Miri‐Moghaddam et al. · 2023 · Biochemical Genetics
58. Lipid-Related Pathophysiology of ASD
    Kelly K. Noah, Elaine Tierney · 2023 · Springer eBooks
59. L’évinacumab : un nouveau médicament dans l’arsenal thérapeutique de l’hypercholestérolémie réfractaire
    Miriam Larouche, Daniel Gaudet · 2024 · Archives des Maladies du Coeur et des Vaisseaux - Pratique
60. Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins
    Sergio Fazio, MacRae F. Linton · 2015 · Elsevier eBooks
61. ANGPTL3 binds to PCSK9 to coordinately regulate intracellular lipid homeostasis
    Simone Bini, Valeria Pecce, Alessandra Pinzon Grimaldos, Alessia Di Costanzo, Ilenia Minicocci, Stella Covino, Daniele Tramontano, Silvia Piconese, Laura D’Erasmo, Marcello Arca · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
62. Angiopoietin like protein 3 regulates low-density lipoprotein transport through aortic endothelial cells via endothelial lipase
    Yen Way Isabell Trinh, Grigorios Panteloglou, Evelina Voloviceva, Museer A. Lone, Stephanie Bernhard, Eveline Schlumpf, Kathrin Frey, Lucia Rohrer, Mary Juliette Melo Gonzales, Thomas A. Lutz et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
63. Synergic combination of the monogenic ANGPTL3 p.H343R variant and a polygenic predisposition in a family with hypobetalipoproteinemia
    Manon Levy, Alexandre Janin, Oriane Marmontel, Anthony Fourier, Séverine Nony, Antoine Rimbert, Bertrand Cariou, Sylvie Fimbel, Sybil Charrière, Philippe Moulin et al. · 2025 · Atherosclerosis
64. Lipid deprivation amplifies type I IFN responses in monocytes through prenylation: insights from familial combined hypolipidemia type 2
    Alessandra Pinzon Grimaldos, Ilenia Pacella, Tamara Giacomelli, Simone Bini, Alessia Di Costanzo, Ilenia Minicocci, Laura D’Erasmo, Giuseppe Pietropaolo, Valerio Licursi, Marcello Arca et al. · 2025 · Journal of Translational Medicine
65. Additional file 1 of A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
    Xiaozhi Hu, Jiajun Fan, Ma, Qianqian, Lei Han, Cao, Zhonglian, Xu, Caili, Jingyun Luan, Jing, Guangjun, Yanyang Nan, Wu, Tao et al. · 2022 · Figshare
66. Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia
    Archna Bajaj, Michael McGuire, Suzanne Shugg, Richard Godin, James A. Underberg · 2026 · American Journal of Preventive Cardiology
67. Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
    Valentina Flagiello, Emelie Barreby, Umberto Vespasiani Gentilucci, Stefano Romeo · 2026 · Journal of Internal Medicine